SA
Log In
RMD
OverviewIntelligenceChart

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating
Hold
24 analysts·High coverage
54%
Rating Distribution
Strong Buy
00%
Buy
1354%
Hold
938%
Sell
28%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 28% higher.

Bear Case
$255.00
+12%
Consensus
$292.75
+28%
Bull Case
$345.00
+51%
Price Range24 analysts
Low
Consensus
High
$255.00
$345.00
Current Target
Current Price
$228.12
Upside to Target
$64.63

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+7.43%
EPS+10.96%
FY2028
Rev+6.89%
EPS+9.65%
FY2029
Rev+7.38%
EPS+6.68%

Earnings Surprises

Recent Analyst Actions

Apr 13, 2026Evercore ISI
ResMed price target lowered to $255 from $300 at Evercore ISI
Target:$255.00
+11.7%from $228.33
Jan 30, 2026RBC Capital
ResMed price target raised to $314 from $311 at RBC Capital
Target:$314.00
+23.6%from $254.08
Jan 30, 2026Stifel Nicolaus
ResMed price target raised to $265 from $260 at Stifel
Target:$265.00
+2.9%from $257.61
Jan 30, 2026KeyBanc
ResMed price target raised to $302 from $299 at KeyBanc
Target:$302.00
+17.2%from $257.61
Jan 30, 2026Robert W. Baird
ResMed price target raised to $281 from $275 at Baird
Target:$281.00
+9.1%from $257.61
Jan 30, 2026Piper Sandler
ResMed price target raised to $275 from $270 at Piper Sandler
Target:$275.00
+6.8%from $257.61
Dec 18, 2025Stifel Nicolaus
ResMed (RMD) PT Lowered to $260 at Stifel
Target:$260.00
+5.7%from $245.94
Dec 16, 2025Robert W. Baird
ResMed downgraded to Neutral from Outperform at Baird
Target:$275.00
+8.7%from $253.07
Dec 12, 2025UBS
ResMed (RMD) PT Raised to $345 at UBS
Target:$345.00
+37.2%from $251.38
Nov 3, 2025Robert W. Baird
ResMed price target lowered to $300 from $320 at Baird
Target:$300.00
+21.5%from $246.88
Oct 31, 2025KeyBanc
ResMed price target raised to $299 from $298 at KeyBanc
Target:$299.00
+22.5%from $244.12
Oct 31, 2025Morgan Stanley
ResMed price target raised to $305 from $304 at Morgan Stanley
Target:$305.00
+20.9%from $252.26
Oct 21, 2025Morgan Stanley
ResMed price target raised to $304 from $298 at Morgan Stanley
Target:$304.00
+12.0%from $271.41
Oct 13, 2025Wells Fargo
ResMed initiated with an Equal Weight at Wells Fargo
Target:$280.00
+2.9%from $272.00
May 20, 2025Morgan Stanley
Morgan Stanley sees 'modest' earnings impact to ResMed from Apnimed
Target:$286.00
+15.3%from $248.14
Apr 24, 2025KeyBanc
ResMed price target raised to $274 from $269 at KeyBanc
Target:$274.00
+17.8%from $232.65
Apr 16, 2025Mizuho Securities
ResMed price target lowered to $265 from $280 at Mizuho
Target:$265.00
+25.3%from $211.49
Mar 5, 2025Stifel Nicolaus
ResMed price target lowered to $240 from $250 at Stifel
Target:$240.00
+7.2%from $223.83
Jan 31, 2025Piper Sandler
ResMed price target raised to $260 from $252 at Piper Sandler
Target:$260.00
+10.1%from $236.18
Dec 12, 2024Stifel Nicolaus
ResMed initiated with a Hold at Stifel
Target:$250.00
+3.1%from $242.51
Oct 1, 2024RBC Capital
ResMed (RMD) PT Raised to $224 at RBC Capital
Target:$224.00
-6.3%from $238.95
Sep 23, 2024Robert W. Baird
Baird Starts ResMed (RMD) at Outperform
Target:$280.00
+13.7%from $246.18
Sep 18, 2024Wolfe Research
Wolfe Research Downgrades ResMed (RMD) to Underperform
Target:$180.00
-28.3%from $250.88
Apr 10, 2024RBC Capital
ResMed (RMD) PT Raised to $187 at RBC Capital
Target:$187.00
-3.7%from $194.27
Apr 1, 2024Stifel Nicolaus
ResMed (RMD) PT Raised to $224 at Stifel
Target:$224.00
+13.1%from $198.03

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance